Previous 10 | Next 10 |
Boston , MA (July 5, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (Nasdaq: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP ® companion diagnostics for p...
2023-06-28 01:55:32 ET Clinical-stage pharmaceutical company, Allarity Therapeutics ( NASDAQ: ALLR ) clarifies the effective date of its contemplated reverse stock split. The company is clarifying that the reverse stock split will not be effected on June 27, 2023,...
Press Release BOSTON, MA (June 27, 2023) – Allarity Therapeutics, Inc. (NASDAQ: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP ® companion diagnos...
Meeting adjourned to Friday, June 23 , 2023 at 1 :00 p .m. Eastern Time Press release BOSTON, MA (June 20, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage ...
Phase 2 study e valuating the u tility of a DRP ® c ompanion d iagnostic for cisplatin support s its ability to predict drug response in certain breast cancer patients Boston , M A (May 30, 2023) — A...
CAMBRIDGE, MA / ACCESSWIRE / April 27, 2023 / Recently, Allarity Therapeutics, Inc. (NASDAQ:ALLR) announced plans to speed up its Phase 2 clinical trial for IXEMPRA®, the clinical-stage pharma company's metastatic breast cancer treatment. Already approved by the Food and Drug Administ...
2023-04-19 12:49:23 ET Gainers: SAI.TECH Global Corporation ( SAI ) +48% . Bed Bath & Beyond ( BBBY ) +40% . VYNE Therapeutics ( VYNE ) +34% . Boqii Holding Limited ( BQ ) +30% . CXApp ( CXAI ) +19% . Western Alliance Ban...
2023-04-19 10:05:08 ET Gainers: Vyne Therapeutics ( VYNE ) +32% . Ensysce Biosciences ( ENSC ) +23% . Legend Biotech ( LEGN ) +20% . Tempest Therapeutics ( TPST ) +16% . Evoke Pharma ( EVOK ) +14% . Losers: Allarity T...
2023-04-19 09:48:03 ET Allarity Therapeutics ( NASDAQ: ALLR ) shares plunged 40% on Wednesday after the pharmaceutical company priced its securities offering to raise around $7.5M in gross proceeds. The offering consists of 2,869,330 shares of common stock, 7,130,670 p...
Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering BOSTON, MA (April 19, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeu...
News, Short Squeeze, Breakout and More Instantly...
Allarity Therapeutics Inc. Company Name:
ALLR Stock Symbol:
NASDAQ Market:
Allarity Therapeutics Inc. Website:
A look at the top 10 most actives in the United States Sangamo Therapeutics Inc. (SGMO) rose 50.7% to $0.604699 on volume of 90,844,210 shares Selina Hospitality PLC (SLNA) rose 7.7% to $0.028 on volume of 57,431,570 shares NuZee Inc. (NUZE) rose 260.1% to $3.7094 on volume of 53,639,595 ...
Boston (July 24, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, encourages its stockholders to participate actively in the ...
Current Cash Balance of $20 million Expected to Provide Runway Into 2026 Allarity to Pause Use of ATM Cap Table Successfully Cleaned Up Allarity’s Stenoparib Shows Extended Duration of Phase 2 Clinical Benefit Boston (July 22, 2024)—Allarity The...